Hetero gets DGCI’s approval for hepatitis C drug
Drug maker Hetero has received approval from DCGI to market generic version of Gilead’s Harvoni, a drug used in the treatment of Hepatitis C, in the country.
Hetero is the first company in India to receive the approval for the fixed-dose combination Ledipasvir-Sofosbuvir (90mg/400mg) from Drug Controller General of India (DCGI), the company said in a statement.
Following the non-exclusive licensing agreement signed with Gilead Sciences in September last year, to manufacture and market chronic hepatitis C medicines, Hetero is all set to launch the fixed-dose combination therapy Ledipasvir-Sofosbuvir for Indian patients, it added. Read More
Comment Here